GHK-Cu (Copper Peptide): A Research Overview

Research-use context. Educational summary of the published literature for laboratory audiences. Not medical advice, not a dosing guide, not a recommendation for human use. All VANTA products are sold strictly for in-vitro and laboratory research use only.

TL;DR: GHK-Cu is the copper(II) complex of the naturally occurring tripeptide GHK (glycyl-L-histidyl-L-lysine). First isolated by Loren Pickart in 1973, it is among the most-studied copper peptides and is examined in skin-regeneration, wound-healing, and anti-aging research. Its plasma levels decline with age. It is not an FDA-approved drug.

Last reviewed: July 2026.

What is GHK-Cu?

GHK-Cu is the copper(II) complex of GHK — the tripeptide glycyl-L-histidyl- L-lysine. GHK occurs naturally in human plasma and was first isolated by Loren Pickart in 1973, in work showing that a plasma fraction could shift older liver cells toward a younger protein-expression pattern. GHK has a high affinity for copper ions and usually exists as the GHK-Cu complex. It is among the most studied copper peptides, and a notable point of mechanistic interest is that some collagen- stimulating activity may originate from the copper ion itself rather than the peptide alone.

A relevant biological backdrop: GHK levels in human plasma decline with age, which is part of why it is studied in aging and tissue-remodeling contexts.

How does GHK-Cu work?

GHK-Cu works chiefly as a modulator of tissue remodeling. In preclinical and some clinical models it has been reported to stimulate matrix synthesis, support blood-vessel formation and fibroblast function, and influence the expression of a broad set of human genes:

Collagen / matrix synthesis. GHK-Cu has been reported to stimulate synthesis of collagen, elastin, and glycosaminoglycans, and to modulate matrix metalloproteinases and their inhibitors (TIMP-1/2) — positioning it as a regulator of tissue remodeling.
Angiogenesis and fibroblast support. Studies describe promotion of blood- vessel formation and restoration of function in damaged or irradiated fibroblasts.
Gene modulation. Analyses using the Broad Institute’s Connectivity Map have reported GHK influencing expression of large numbers of human genes, including DNA-repair-associated genes — the basis of the “genome-resetting” framing in the review literature.

What does the research on GHK-Cu actually show?

GHK-Cu has an unusually deep evidence base for a peptide, spanning foundational work from the 1980s–2000s through recent reviews, and including some human skin studies. The strongest data is topical and dermatological; systemic claims are less supported, and effects are concentration-dependent.

An unusually deep and old evidence base for a peptide, spanning foundational work from the 1980s–2000s through recent reviews — including some human skin studies (e.g. copper-tripeptide regimens on laser-resurfaced skin).
Mechanistic caveats matter. Patent and review literature note that collagen stimulation may derive substantially from the copper ion, that higher GHK-Cu concentrations can produce skin irritation, and that effects are concentration- dependent (nanomolar ranges are commonly cited as active and non-toxic in vitro).
Much of the strongest data is dermatological/topical; systemic claims are less well supported.

How does GHK-Cu compare to related peptides?

GHK-Cu is frequently examined in skin-regeneration and anti-aging research, and is discussed alongside BPC-157 in broader wound-healing/tissue-repair reviews. It also appears in bone-healing and pulmonary (COPD) research contexts.

What is the regulatory status of GHK-Cu in 2026?

As of mid-2026, GHK-Cu is not an FDA-approved drug. It is widely used as a cosmetic ingredient in topical skincare, which is a separate regulatory category from injectable or systemic use. In the 2026 peptide reclassification, GHK-Cu was among the compounds reported removed from the FDA’s Category 2 restricted list (effective April 23, 2026), potentially restoring a compounding pathway under physician prescription — though that is distinct from FDA drug approval, and GHK-Cu is not among the seven peptides on the July 23–24, 2026 Pharmacy Compounding Advisory Committee 503A agenda. VANTA supplies GHK-Cu strictly for in-vitro and laboratory research use only.

Laboratory handling

Storage (lyophilized): cold, protected from light; long-term at −20 °C.
After reconstitution: refrigerated (2–8 °C), protected from light (copper complexes are light-sensitive); used within the lab’s protocol window.
Verification: confirm identity/purity against the batch COA (HPLC, mass spec).

VANTA supplies GHK-Cu as a ≥99% purity research peptide with a batch-specific COA. See our Certificates of Analysis page.

Frequently asked (research) questions

Why is it always paired with copper? GHK binds copper ions with high affinity and is typically studied as the GHK-Cu complex; some of its documented activity appears linked to the copper ion.

Are GHK-Cu’s effects human-validated? There is more human (especially dermatological) data than for many research peptides, but it remains research/cosmetic-context evidence, not an approved therapeutic indication.

Is GHK-Cu FDA-approved or legal in 2026? GHK-Cu is not an FDA-approved drug, though it is common in topical cosmetics. It was reported removed from the FDA’s Category 2 restricted list in 2026, which is separate from drug approval. VANTA supplies it for research use only.

References

Pickart L, et al. Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells. Nature. 1980;288:715–717. doi:10.1038/288715a0.
Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008;19(8):969–988.
Pickart L, Vasquez-Soltero JM, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide… (review). Int J Mol Sci / related. PubMed: 29986520.
GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. PMC4508379.

Verify each source independently. This summary is research context only and does not describe or recommend human use.